Drug intelligence / Profile preview

LS-002

Development stage
Unknown
Lead developer
Lifescient
Modality
Small Molecules
Administration
Injectable
01

Overview

LS-002 is a long-acting injectable formulation of the analgesic buprenorphine, developed by Lifescient for the management of pain in dogs. The product utilizes Lifescient's proprietary "Life-Sustained" (LS) technology, which is a lipid-based delivery system designed to provide sustained release of the active ingredient over several days from a single administration. Buprenorphine is a potent opioid that acts as a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor, providing effective analgesia with a wider safety margin than full mu-agonists. LS-002 is intended to provide consistent, multi-day pain control in canine patients, particularly following surgical procedures, thereby improving clinical compliance and reducing the need for frequent redosing in veterinary settings.

02

Targets

DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)NOP (Nociceptin/orphanin FQ peptide receptor)

Beyond the preview

Go deeper on LS-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on LS-002.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call